73 results
F-1
EX-4.8
IINN
Inspira Technologies Oxy B.H.N. Ltd
9 May 24
Registration statement (foreign)
5:02pm
Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
17 Apr 24
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
6:43am
statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of the Company’s products and potential
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
10 Apr 24
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
8:50am
are potentially further expanding the benefits of the INSPIRA ART.”
Dr. Manuela Hod, CEO of Ennocure, stated: “Our team is positive … it discusses the potential benefits of the Company’s products and potential products, the potential advantages of the bio-electronic treatment
6-K
EX-10.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager
8:46am
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
25 Mar 24
Inspira™ Technologies Reports Full Year 2023 Financial Results
9:27am
is using forward-looking statements when it discusses the benefits of its various products, its expected regulatory submissions and the timing
6-K
EX-99.1
hgy0c1s1o2ra8uebry4g
18 Mar 24
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
7:08am
6-K
EX-99.1
2tkgcderrfvkz
4 Mar 24
Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days
9:25am
6-K
EX-99.1
lbpksacb
27 Feb 24
Report of Foreign Private Issuer
7:15am
6-K
EX-99.3
rkgkw
27 Feb 24
Report of Foreign Private Issuer
7:15am
6-K
EX-99.1
6wbn66kvqcx hofq26v
22 Feb 24
Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies
9:18am
6-K
EX-99.1
r3d4cl1a5k9o3s3
14 Feb 24
Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
9:18am
424B5
dcswd3m3rqen
28 Dec 23
Prospectus supplement for primary offering
9:28am
6-K
EX-4.1
dxtk0n6yvlh00t
27 Dec 23
Inspira Announces $3.88 Million Registered Direct Offering
4:46pm
6-K
EX-10.1
9s7d2ehyj 46z30z
27 Dec 23
Inspira Announces $3.88 Million Registered Direct Offering
4:46pm
6-K
EX-4.2
wrlyts k9aj8jss8y0
27 Dec 23
Inspira Announces $3.88 Million Registered Direct Offering
4:46pm
6-K
EX-99.1
eh3sy5fu6
26 Dec 23
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
4:01pm
6-K
EX-99.1
xk2j1c 75bn29b
29 Nov 23
Report of Foreign Private Issuer
9:22am
6-K
EX-99.1
2wdxinuepul1ntdaq
7 Nov 23
Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology
7:55am